Impact of Statin Use on Outcomes in Triple Negative Breast Cancer
Open Access
- 1 January 2017
- journal article
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 8 (11) , 2026-2032
Abstract
Purpose: We sought to investigate if the use of HMG Co-A reductase inhibitors (statins) has an impact on outcomes among patients with triple negative breast cancer (TNBC).Keywords
This publication has 24 references indexed in Scilit:
- Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3aBreast Cancer Research and Treatment, 2015
- Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?Oncotarget, 2015
- Cholesterol and breast cancer pathophysiologyTrends in Endocrinology & Metabolism, 2014
- Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathwayBiochemical and Biophysical Research Communications, 2013
- Mevalonate Metabolism Regulates Basal Breast Cancer Stem Cells and Is a Potential Therapeutic TargetStem Cells, 2012
- Effect of metformin on survival outcomes in diabetic patients with triple receptor‐negative breast cancerCancer, 2011
- Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast CancerJournal of Clinical Oncology, 2011
- Triple-Negative Breast CancerNew England Journal of Medicine, 2010
- Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivorsBreast Cancer Research and Treatment, 2007
- Triple-Negative Breast Cancer: Clinical Features and Patterns of RecurrenceClinical Cancer Research, 2007